Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 19:06:42 +0200Fri, 05 Apr 2024 15:30:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Besponsa, Inotuzumab ozogamicin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology;Oncology, PIP number: P/0079/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001429-pip01-13-m07Opinion/decision on a Paediatric investigation plan (PIP): Besponsa, Inotuzumab ozogamicin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology;Oncology, PIP number: P/0079/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001429-pip01-13-m07Fri, 05 Apr 2024 15:30:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Date of authorisation: 28/06/2017, Revision: 10, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/besponsaHuman medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Date of authorisation: 28/06/2017, Revision: 10, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/besponsaThu, 15 Feb 2024 14:26:00 +0100Human medicineBesponsa : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/wc500231262_en.pdfBesponsa : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/wc500231262_en.pdfThu, 13 Jul 2017 12:11:00 +0200Human medicine